Announcement • Apr 23
PreveCeutical Medical Inc. announced that it expects to receive CAD 1 million in funding Preveceutical Medical Inc announced a non-brokered private placement of up to 40,000,000 units at an issue price of CAD 0.025 per unit for gross proceeds of CAD 1,000,000 on April 22, 2026. Each unit consists of one common share of the company and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase an additional share at an exercise price of CAD 0.05 per warrant share for a period of two years from the closing of the offering. Finders' fees may be paid in connection with the offering. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the closing. Completion of the offering remains subject to certain conditions, including, without limitation, confirmation of no objection from the CSE. New Risk • Dec 02
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.3m free cash flow). Share price has been highly volatile over the past 3 months (36% average weekly change). Negative equity (-CA$7.4m). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (CA$15.0m market cap, or US$10.7m). Announcement • Aug 06
PreveCeutical Medical Inc. announced that it expects to receive CAD 1 million in funding PreveCeutical Medical Inc. announced a non-brokered private placement of up to 25,000,000 units at a price of CAD 0.04 per unit for gross proceeds of up to CAD 1,000,000 on August 5, 2025. Each unit consists of one common share and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase an additional share at an exercise price of CAD 0.06 per warrant share for a period of two years from the closing of the offering. Finders' fees may be paid in connection with the offering. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the closing. Completion of the offering remains subject to certain conditions, including, without limitation, confirmation of no objection from the Canadian Securities Exchange. Announcement • Jun 17
PreveCeutical Medical Inc., Annual General Meeting, Aug 15, 2025 PreveCeutical Medical Inc., Annual General Meeting, Aug 15, 2025. Announcement • Jun 12
PreveCeutical Medical Inc. announced that it expects to receive CAD 0.75 million in funding Preveceutical Medical Inc. announced a non-brokered private placement of up to 15,000,000 units at an issue price of CAD 0.05 per unit for gross proceeds of CAD 750,000 on June 11, 2025. Each unit consists of one common share of the company and one-half of one share purchase warrant. Each warrant entitles the holder thereof to purchase an additional share at an exercise price of CAD 0.08 for a period of 24 months from the closing of the offering. Finders' fees may be paid. All securities issued in connection with the offering will be subject to a statutory hold period expiring four months and one day after the closing. Completion of the offering remains subject to certain conditions, including, without limitation, confirmation of no objection from the CSE. Announcement • May 23
PreveCeutical Medical Inc. announced that it has received CAD 0.748383 million in funding On May 22, 2025, the PreveCeutical Medical Inc. closed the transaction by raising final tranche of CAD 158,382. In connection with the this tranche, the Company paid finders fees to an eligible finder comprised of CAD 12,670.56 in cash and issued 422,352 Finder’s Warrant. The Finder’s Warrant are exercisable into one additional Share at an exercise price of CAD 0.05 per share for 24 months from the closing of final tranche subject to the Acceleration Right. All securities issued in relation to the final tranche are subject to a hold period expiring four months and one day after closing in accordance with applicable securities laws. Recent Insider Transactions Derivative • Jan 02
Director exercised options to buy CA$50k worth of stock. On the 30th of December, Linnea Olofsson exercised options to buy 2m shares at a strike price of around CA$0.027, costing a total of CA$55k. As of today, Linnea currently holds no shares directly. Company insiders have collectively bought CA$66k more than they sold, via options and on-market transactions, in the last 12 months. New Risk • Jun 09
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$32k free cash flow). Share price has been highly volatile over the past 3 months (36% average weekly change). Negative equity (-CA$5.4m). Revenue is less than US$1m. Market cap is less than US$10m (CA$13.5m market cap, or US$9.81m). Minor Risk Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). New Risk • May 30
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$32k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$32k free cash flow). Share price has been highly volatile over the past 3 months (35% average weekly change). Negative equity (-CA$5.4m). Revenue is less than US$1m. Market cap is less than US$10m (CA$13.4m market cap, or US$9.76m). Announcement • May 03
PreveCeutical Medical Inc. announced that it expects to receive CAD 0.25 million in funding PreveCeutical Medical Inc. announced a private placement for gross proceeds of up to CAD 250,000 on May 2, 2024. Announcement • Sep 20
PreveCeutical Medical Inc. and Endosane Pharmaceuticals GmbH Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD and Pharmacologically Relevant Doses Following Intranasal CBD Application PreveCeutical Medical Inc. announced that Endosane Pharmaceuticals GmbH will proceed with its research initiative focused on preclinical studies to evaluate the brain delivery characteristics of sol-gel technology and whether pharmacologically relevant concentrations of CBD can be achieved with this technology. The company's commitment to advancing medical research is demonstrated through its comprehensive research proposal for a first preclinical study in rats. The primary objectives of this study include: Investigating the potential of sol-gel technology for rapid delivery of CBD to the brain. This includes assessing the amounts achieved, regional distribution, and time course of CBD uptake in the brain. Objective 2: Demonstrating the pharmacological relevance of brain CBD concentrations following intranasal application. Study Design: The research will be conducted through a series of well-structured experiments: Experiment 1: Rats will be administered up to three doses of CBD in sol-gel form via nasal spray. Evaluation will be carried out at six different time points. Brain regions such as the olfactory bulb, prefrontal cortex, parietal cortex, pons, and cerebellum will be assessed, and concentrations of CBD and its metabolites will be quantified using a validated LC-MS/MS assay. Experiment 2: A separate group of rats will receive intranasal CBD administration. Cerebrospinal fluid (CSF) and cardiac blood samples will be collected at specific time points based on the findings from Experiment 1. CBD and metabolite concentrations will be measured using validated LC-MS/MS assays. Experiment 3: Building upon the outcomes of Experiment 1, the study will assess intranasal CBD doses that yield significant brain exposure in rat models of anxiety and chronic pain. These are two conditions in which CBD has already demonstrated preclinical efficacy. Collaborative Efforts: Endosane is collaborating closely with the Brain and Mind Centre of the University of Sydney. A significant breakthrough in this partnership has been the identification of anandamide as a potential blood surrogate marker for CBD's brain activity. The research team has also examined the temporal changes in serum. PreveCeutical and Endosane dedication to research in the field of CBD delivery and pharmacology underscores its commitment to advancing medical knowledgeand improving patient outcomes. The company remains focused on scientific innovation, working diligently to pave the way for novel treatments and therapies. New Risk • Aug 06
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: CA$13.4m (US$10.00m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$78k free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-CA$4.9m). Revenue is less than US$1m. Market cap is less than US$10m (CA$13.4m market cap, or US$10.00m). Minor Risk Shareholders have been diluted in the past year (2.3% increase in shares outstanding). Announcement • Jul 25
PreveCeutical Medical Inc. Files Cyclic Peptides and Uses Thereof in EU and Australia PreveCeutical Medical Inc. announced that it is furthering the progress Cyclic peptides and uses thereof of its patent families. PreveCeutical's patent family based on PCT/AU2021/051545 (P113135.PCT, Cyclic peptides and uses thereof), has now entered the national phase in Europe and Australia. The Australian case has been allocated application no. 2021408143, and the European case has been allocated application no. EP21908152.8. This is in addition to patent applications having recently been filed in the US and Canada. PreveCeutical is prosecuting the patent applications to maximize the scope of protection available in those countries and to ensure that effective and secure patents are obtained as the company continue its clinical process. Announcement • Jun 29
PreveCeutical Medical Inc. Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use & Cyclic Peptides and Uses Thereof PreveCeutical Medical Inc. announced that PreveCeutical is furthering the progress of two of its patent families. The patent family based on PCT/AU2021/051383 (P114915, Sol-gel cannabinoid formulation and antiviral use), has now entered the national phase in Europe and Australia. The Australian case has been allocated application no. 2021384063, and the European case has been allocated application no. EP21893149.1. This is in addition to patent applications having recently been filed in the US and Canada. PreveCeutical's patent family based on PCT/AU2021/051545 (P113135.PCT, Cyclic peptides and uses thereof), has now entered the national phase in the US and Canada. The US case has been allocated the application no. US18/268951, and full filing details in Canada are awaited. PreveCeutical is prosecuting the patent applications to maximize the scope of protection available in those countries and to ensure that effective and secure patents are obtained as the company continue its clinical process. Although PreveCeutical believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate or successful. Board Change • Nov 16
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 6 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Chairman & CEO Stephen Van Deventer is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Announcement • Oct 21
Preveceutical Medical Inc. Announces Appointment of Kathleen Rotika to Board of Directors PreveCeutical Medical Inc. announced the appointment of Ms. Kathleen Rotika ("Kathy") to the Company's board of directors. Kathy is a CPA and Principal of Somerset CPA's P.C. She is a finance, operations, and strategy-focused executive with extensive experience with large medical groups. Her experience includes financial performance improvement, business development, operational process improvement, information reporting/analytics, treasury management, budgeting and payor contracting/relations. Kathy has been appointed to the audit committee of the Board. Announcement • Sep 17
PreveCeutical Medical Inc. Announces Resignation of Sachin Nanavati as A Member of the Company's Board of Director, Effective September 16, 2022 PreveCeutical Medical Inc. announces the resignation of Mr. Sachin Nanavati as a member of the Company's board of director (the "Board") for personal reasons effective September 16, 2022. Announcement • Sep 07
PreveCeutical Medical Inc. Appoints Mr. Sachin Nanavati to Board of Directors PreveCeutical Medical Inc. announces the appointment of Mr. Sachin Nanavati to the Company's board of directors (the "Board") effective September 1, 2022. Sachin is currently the Head of Industry, Healthcare with Google Inc. He has vast knowledge and experiencewith healthcare and technology. Sachin was a founding member of Meta (Facebook)'s Health Team, which created a go-to-market strategy and narrative focused on supporting pharmaceutical clients' digital marketing. He was previously a pharmaceutical sales representative with GlaxoSmithKline and a hospital sales specialist with Novartis Pharmaceuticals. Dr. Olofsson and Mr. Nanavati have been appointed to the Board's audit committee. Board Change • Jul 16
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Chairman & CEO Stephen Van Deventer is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Announcement • May 29
PreveCeutical Medical Inc. Announces Management Changes PreveCeutical Medical Inc. announced the resignation of Mr. Anderson and Mr. Lotz and the appointment of Dr. Linna Olofsson to the Company's board of directors (the "Board"). Resignation of Directors: Mr. Keith Anderson and Mr. Mark Lotz will be stepping down as directors of the Company effective May 31, 2022, to allow them more time to focus on their business. Appointment of Director: The Company is pleased to appoint Dr. Olofsson to the Board, effective June 1, 2022. Dr. Olofsson will also be a member of the Board's audit committee and the corporate governance and nominating committee. Dr. Olofsson is a business entrepreneur with a background in development, clinical trials, and commercialization. PreveCeutical has retained the services of Empire Relations Group effective June 1, 2022, for three months, at a fee of USD 2,500 per month, to assist with investor awareness. Board Change • Apr 27
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 6 experienced directors. No highly experienced directors. Chairman & CEO Stephen Van Deventer is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Nov 27
PreveCeutical Files Provisional Patent Application for D-Amino Acid Peptides PreveCeutical Medical Inc. announce it has filed a provisional application at the Australian Patent Office on November 18, 2021, entitled "Peptides and Uses Thereof", application number 2021903722, with the aim of seeking protection for certain peptides comprising D-amino acids and their use in methods of treating brain cancer. Compounds in these Peptides may be suitable for the treatment of cancers in which extracellular matrix metalloprotease ("MMP") or other proteinases such as urokinase-type plasminogen activator (uPa) are implicated. MMPs are known to exert effects on the extracellular microenvironment, for example, degradation of the extracellular matrix, thereby allowing cancer cell invasion. Gliomas, which represent 40% to 45% of all intracranial tumours, are characterized by their potent ability to infiltrate surrounding normal brain tissue, making them a challenge to treat. Glioblastoma multiforme ("GBM") is the most common and fatal form of brain cancer, affecting adults between the ages of 45 and 60 years. Current treatments for GBM include chemotherapy, radiotherapy and surgery, with the survival of most patients being about one year from diagnosis. The provisional patent application is to protect the peptides comprising D-amino acids identified in the BSV research project. These peptides have the potential, at least in part, to work as an MMP inhibitor. Announcement • Jun 01
PreveCeutical Medical Inc. Provides Corporate Update PreveCeutical Medical Inc. provided the following update. The Company's priority is to create shareholder value through the development and commercialization of products and delivery technology. The Company has partnered with UniQuest Pty Limited and the University of Queensland through its Australian subsidiary, PreveCeutical (Australia) Pty Ltd, to conduct research and development. The Company is very pleased with the positive outcome from the successful completion of the following programs: Stabilization of Blue Scorpion Venom was completed in October 2019; Sol-gels for Nasal Delivery of Cannabinoids was completed in June 2020; COVID-19 Sol-Gel Formulation Development was completed in November 2020. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain COVID-19 at this time; Disulfide Linker Technology in Engineering Analgesic Peptides completed in February 2021. The Company is creating a library of patentable intellectual property and forming partnerships to develop and commercialize patentable delivery of therapies and products. The Company has filed the following provisional patent applications at the Australian Patent Office: 2020-07-01, application number 2020902233, "Peptides and Uses Thereof", aiming to seek protection for certain peptides analogues of dynorphin and their use in pain management; 2020-08-31, application number 2020903102, "Cannabinoid Formulations and Methods of Use", to seek the protection of its sol-gel formulations containing cannabinoids for nasal delivery; 2020-11-20, application number 20200904291, "Sol-Gel Cannabinoid Formulation and Antiviral Use", aiming to seek protection for certain cannabinoid formulations and their use in the prevention and treatment of COVID-19 caused by SARS-CoV-2 infection; 2020-12-22, application number 2020904798, "Cyclic Peptides and Uses Thereof", aiming to seek the protection for certain cyclic peptides and their use in the prevention and treatment of brain cancer. Announcement • Mar 16
PreveCeutical Medical Inc. Announces the Appointment of Aditya Bahl as an Advisor and Consultant PreveCeutical Medical Inc. announced the appointment of Aditya Bahl as an advisor and consultant for the Company. Mr. Bahl brings over 20 years of experience in pharmaceutical marketing and clinical development. He is the CEO and founder of RAS LSS, a boutique healthcare consulting group based in Germany. He provides strategic guidance to biotechnology and pharmaceutical companies on franchise/product strategy, clinical development and commercialization. Mr. Bahl, who worked as Director of Competitive Intelligence at Novartis Pharma AG and as Senior Consultant for Janssen Research and Development, is known for his entrepreneurship, creativity and is a passionate speaker for innovations in healthcare. He has significant leadership experience across several therapeutic areas, including oncology and biosimilars. Announcement • Feb 24
PreveCeutical Medical Inc. Appoints Dr. Linnéa Olofsson as Advisor and Consultant PreveCeutical Medical Inc. announced the appointment of Dr. Linnéa Olofsson as an advisor and consultant for the company. Dr. Olofsson will be working with team in implementing strategies for the commercialization of products. With her scientific background and ability to understand the needs in the medical field, she will be collaborating to bring important solutions to meet goals and objectives. Announcement • Feb 03
PreveCeutical Medical Inc. Announces Successful Completion of its Non-Addictive Analgesic Program PreveCeutical Medical Inc. announced the successful completion of its non-addictive analgesic program ("Analgesic Program"). The Analgesic Program started in July 2018 to discover and develop peptide-based therapeutics for moderate to severe pain and inflammation. The Company has received the final research project report from UniQuest Pty Ltd. for this discovery program, which utilized a proprietary disulfide linker technology. Announcement • Jan 06
PreveCeutical Medical Inc. Files Provisional Patent Application for its BSV Peptide PreveCeutical Medical Inc. announced it has filed a provisional application at the Australian Patent Office on December 22, 2020, entitled "Cyclic Peptides and Uses Thereof", application number 2020904798, with the aim of seeking protection for certain cyclic peptides and their use in prevention and treatment of brain cancer. Peptides derived from the Blue Scorpion Venom ("BSV") have shown promise in delineating glioma (brain cancer) tissue and preventing the invasion of gliomas through inhibition of extracellular matrix metalloprotease (MMP). PreveCeutical sought to identify and screen novel peptides from the Caribbean Blue Scorpion venom, with a view to developing their own treatment for the management of glioblastoma multiforme (GBM). The provisional patent application is to protect the lead peptides identified in the BSV research that appear to show the most potential for further development as therapeutic agents in the management of GBM. Announcement • Nov 24
PreveCeutical Medical Inc., Annual General Meeting, Feb 05, 2021 PreveCeutical Medical Inc., Annual General Meeting, Feb 05, 2021. Announcement • Oct 11
PreveCeutical Medical Inc. Announces Update for Covid-19 Therapy PreveCeutical Medical Inc. inform that in reference to its current work to develop medical countermeasures in response to COVID-19, PreveCeutical has received notification from the Strategic Innovation Fund ("SIF") that its proposal, which was part of the second phase of Canada's National Medical Research Strategy in response to COVID-19, will not be receiving further consideration under this program. SIF has provided PreveCeutical with alternatives through which support for this project could be pursued. PreveCeutical's cannabis sol-gel program to address the COVID-19 pandemic is scheduled to be completed by the end of October 2020. Once the project is completed and PreveCeutical has received a final report, it will submit a revised application which will include further information and scientific data from the final report. PreveCeutical is working on securing funds from other sources and is continuing to work with Veristat to prepare for the Sol-gel COVID-19 clinical trials. The treatment under this program is planned on being a self-administered, over-the-counter product. Per FDA's website, "Over-the-counter (nonprescription) drug products play an increasingly vital role in America's health care system. OTC drugs are defined as drugs that are safe and effective for use by the general public without seeking treatment by a health professional." As OTC drugs are usually regulated according to their active pharmaceutical ingredient (API) rather than final products, PreveCeutical is anticipating that the required regulatory approval will take a shorter time than if it was a prescription drug. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time. Announcement • Oct 02
PreveCeutical Medical Inc. Appoints Dr. Ajit Shetty as an Advisor PreveCeutical Medical Inc. announce the appointment of Dr. Ajit Shetty as an advisor and consultant for the Company. Dr. Shetty brings his extensive pharmaceutical experience leading commercial and supply chain operations and his significant educational background to the Company. Dr. Shetty spent 36 years at Johnson & Johnson ("J&J") in a wide range of global roles. From 2007 to 2012, he served as Corporate Vice President, Enterprise Supply Chain reporting to the CEO and was responsible for the transformation and optimization of J&J's supply chain. 